Rust, R., Samadzadeh, S., Röper, A., Stahmann, A., Schindler, P., Neumaier, M., . . . Bahr, L. (2026). Application of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as biomarkers in the clinical management of multiple sclerosis (NeuroFilMS): A protocol for an observational cohort study. BMJ open, 16(7), . https://doi.org/10.1136/bmjopen-2025-110058
Cita Chicago Style (17a ed.)Rust, Rebekka, et al. "Application of Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) as Biomarkers in the Clinical Management of Multiple Sclerosis (NeuroFilMS): A Protocol for an Observational Cohort Study." BMJ Open 16, no. 7 (2026). https://doi.org/10.1136/bmjopen-2025-110058.
Cita MLA (9a ed.)Rust, Rebekka, et al. "Application of Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) as Biomarkers in the Clinical Management of Multiple Sclerosis (NeuroFilMS): A Protocol for an Observational Cohort Study." BMJ Open, vol. 16, no. 7, 2026, https://doi.org/10.1136/bmjopen-2025-110058.